Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.52 |
| ▸ | NPY1R | P25929 | 9/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.52 |
| ▸ | NPY2R | P49146 | 6/20 | 0.52 |
| ▸ | CD40 | P25942 | 1/20 | 0.52 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939697 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL30939704 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL31232432 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL5965061 | 1.00 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL31078217 | 0.98 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL30787045 | 0.96 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL30787044 | 0.94 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL30787054 | 0.94 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL30787061 | 0.94 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RCD40 | |
| SCHEMBL29482485 | 0.94 | NPY4R (0.57) | NPY4RNPY1RNPY5RNPY2RCD40 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823255-A | Nur77 methylation site mutant peptide designed based on structural modification and application thereof in promoting embryo implantation | 南京鼓楼医院 | 2025-04-15 | — | — | CN | disclosed |
| US-20250115640-A1 | NEUROPROTECTIVE POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | INNERSE (ZHUHAI) PHARMACEUTICAL CO., LTD. (CN) | 2025-04-10 | — | — | US | disclosed |
| CN-119462849-A | Polypeptide and application thereof in neurodegenerative diseases | 天津智泰生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113735938-B | Neuroprotective polypeptide compound and application thereof | 英纳氏(珠海)药业有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20240368230-A1 | CELL-PENETRATING PEPTIDES COMPRISING MULTIPLE 5-MER ALPHA-HELIX FRAGMENTS AND USES THEREOF | ARTPROBIO CO., LTD. (KR) | 2024-11-07 | — | — | US | disclosed |
| CN-118698507-A | Preparation method of phospholipid affinity monolithic column and application of monolithic column | 无锡萃纯生物材料科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118638745-A | Method for purifying lentivirus | 无锡萃纯生物材料科技有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4378949-A1 | NEUROPROTECTIVE POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | Innerse (Zhuhai) Pharmaceutical Co., Ltd. (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-117003829-A | Oil control polypeptide compound, preparation method and application thereof | 成都凯捷多肽科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-115838434-A | Polypeptide analogue and application thereof in medicine | 南通大学 | 2023-03-24 | — | — | CN | disclosed |
| WO-2023006083-A1 | NEUROPROTECTIVE POLYPEPTIDE COMPOUND AND APPLICATION THEREOF | 英纳氏(珠海)药业有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | BAMBU VAULT LLC (US) | 2022-11-17 | — | — | US | disclosed |
| WO-2005117538-A9 | METHODS AND COMPOSITIONS FOR INHIBITING ABAD/Aβ PROTEIN INTERACTION | UNIV COLUMBIA (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005117538-A2 | METHODS AND COMPOSITIONS FOR INHIBITING ABAD/Aβ PROTEIN INTERACTION | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220362381-A1 | REMOTELY TRIGGERED THERAPY | CD47, HSP90AA1, HSF1 | NPY4R 1871/4885NPY1R 2493/4885NPY5R 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.